Imatinib mesylate is currently the most effective treatment that induces complete remission of chronic myeloid leukemia (CML). However, residual disease may re-expand in some cases and a vaccine-based immunological attack can further reduce the tumor burden. 1, 2 In this setting, effects of imatinib on immune function may be of concern.
3 Studies in vitro have indicated that imatinib inhibits TCR-mediated T-cell activation and proliferation against viral or other immunogenic antigens. 4, 5 One study in mice suggested that imatinib impaired in vitro T-cell proliferation and in vivo delayed-type hypersensitivity (DTH). 6 T-cell inhibition may associate with defective antigen presentation by dendritic cells. 7 Others, b3a2 CML patients with at least 6 months of 'persistent stable' disease during a minimum period of imatinib treatment of 12 months (pts # 1-16), or IFN-a treatment of 24 months (pts # 17-23), were evaluable for the study. Based on the HLA class I and class II binding properties of the peptides contained in the vaccine, the patients HLA haplotype included at least one of the following HLA molecules: HLA A3, A11, B8, DR11, DR1 or DR4. During vaccinations, imatinib (400 mg/day) or IFN-a (3 MU 3 times/week) was not discontinued. The vaccine consisted of four HLA class I binding CML peptides plus a 25mer long peptide (b3a2-25) with binding motifs for HLA class II DR1, DR4 and DR11 mixed with the adjuvant QS-21 (Antigenics Inc., New York, USA), 2 administered subcutaneously six times every 2 weeks. The day before and the day of vaccination, patients received 50 mg/m 2 /day of GM-CSF (Leukine s , Berlex, USA) subcutaneously in proximity of the vaccination site. Peptide-specific immune responses were measured at baseline and after six vaccinations by means of in vivo delayed-type hypersensitivity test (DTH) and in vitro proliferation. DTH was performed as described with an intradermal injection of a mixture of 5 mg/each peptide in PBS without QS-21 and GM-CSF. Injection of PBS only in the opposite arm served as negative control. A positive skin test reaction was defined as 410 mm diameter erythema and induration 24-48 h after injection. Unprimed CD4+ cell proliferation assays were performed using a standard 3 H-thymidine incorporation assay. Unprimed, freshly purified CD4+ cells were incubated for 96 h at 371C with the peptides contained in the vaccine or with control peptides (20 mg/ mL/peptide). 2 however, propose that in vitro exposure to imatinib enhances antigen presentation. 8 In a recent study, we evaluated the ability of 10 CML patients, with persistent minimal residual disease during prolonged treatment with imatinib, to raise specific antitumor T-cell responses after immunization with weakly immunogenic p210-derived peptide antigens associated to QS-21 and GM-CSF as immunological adjuvants.
2 Peptide-specific immune responses were measured at baseline and after six vaccinations in all patients by DTH in vivo test and a proliferation assay with unprimed CD4 þ cells. 2 As an expansion of this previous study, we report additional immunological data on a total of 16 CML imatinib-treated patients and compare their immune responses with a cohort of seven immunized patients in minimal residual disease during INF-a (Table 1) .
At the time of immunization, among the imatinib group (median time of treatment 16 months), 13 patients were in stable cytogenetic and/or molecular residual disease for a median of 12 months and three were cytogenetically 'resistant'. Among the IFN-a group, all patients had a stable cytogenetic disease for a median of 17 months (Table 1) . After immunization, 12/16 imatinib-patients developed a p210 peptide-specific in vivo DTH and all of them demonstrated p210 peptide-specific unprimed CD4 þ T-cell proliferation (median stimulation index: 3.3, range 1.8-25) (Table 1) . Similarly, in the IFN-a group, 4/7 patients developed a DTH response and four of the five evaluated patients developed a peptide-specific CD4 þ T-cell response (median stimulation index 3.9, range 1.8-8.7).
In patients, absolute counts of lymphocyte subsets do not change during imatinib (unpublished). However, B-cells can reduce serum immunoglobulin production. 9 Less is known on T-cell activity in patients treated with imatinib. Our results show that prolonged imatinib therapy (12 months or more) does not preclude induction of significant DTH and CD4 þ T-cell response against a poorly immunogenic tumor peptide antigen. Furthermore, the levels of responses are comparable to those observed in the patients vaccinated under IFN-a treatment, the latter being considered, if anything, an 'immunostimulant' agent. In this context the robust response in the imatinib arm is even more surprising and positive. Obviously, it is difficult to evaluate if imatinib impairs immune responses to some extent in individuals, unless cohorts of healthy volunteers are chosen to be treated with imatinib and then immunized by some antigen. This is the first report to directly deal with the issue of immunosuppressive effect of imatinib in CML patients and our data clearly show that imatinib does not appear to interfere in the T-cell activity involved in an in vivo immune response against poorly immunogenic self-tumor antigens.
